Literature DB >> 20853021

Dexamethasone-induced FKBP51 expression in peripheral blood mononuclear cells could play a role in predicting the response of asthmatics to treatment with corticosteroids.

Eunyoung Chun1, Hyun-Seung Lee, Bo-Ram Bang, Tae-Wan Kim, So-Hee Lee, Ju-Han Kim, Sang-Heon Cho, Kyung-Up Min, You-Young Kim, Heung-Woo Park.   

Abstract

BACKGROUND: Corticosteroids (CSs) are the preferred anti-inflammatory therapy for the treatment of asthma, but the responses of asthmatics to CSs are known to vary. It has thus become important to discover reliable markers in predicting responses to CSs.
METHODS: We performed time-series microarrays using a murine model of asthma after a single dose of dexamethasone, based on the assumption that the gene showing a greater change in response to CSs can also be a potential marker for that finding. We then evaluated the clinical meaning of the gene discovered in the microarray experiments.
RESULTS: We found that the expression of FK506 binding protein 51 gene (FKBP51) in lung tissue markedly increased after dexamethasone treatment in a murine model of asthma. We then measured dexamethasone-induced FKBP51 expression in peripheral blood mononuclear cells (PBMCs) in asthmatics. Dexamethasone-induced FKBP51 expression in PBMCs was significantly higher in severe asthmatics compared with mild-to-moderate asthmatics treated with inhaled CSs. In addition, we found that dexamethasone-induced FKBP51 expression in PBMCs was inversely correlated with improvement in lung function after treatment with orally administered prednisolone in six steroid-naive asthmatics.
CONCLUSION: Dexamethasone-induced FKBP51 expression in PBMCs may be a reliable and practical biomarker in predicting the response to CSs in asthmatics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20853021     DOI: 10.1007/s10875-010-9463-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  25 in total

1.  Non-eosinophilic corticosteroid unresponsive asthma.

Authors:  I D Pavord; C E Brightling; G Woltmann; A J Wardlaw
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

Review 2.  Heterogeneity of therapeutic responses in asthma.

Authors:  J M Drazen; E K Silverman; T H Lee
Journal:  Br Med Bull       Date:  2000       Impact factor: 4.291

3.  An in vitro bioassay to determine individual sensitivity to glucocorticoids: induction of FKBP51 mRNA in peripheral blood mononuclear cells.

Authors:  Harry Vermeer; Brenda I Hendriks-Stegeman; Denise van Suylekom; Ger T Rijkers; Sylvia C van Buul-Offers; Maarten Jansen
Journal:  Mol Cell Endocrinol       Date:  2004-04-15       Impact factor: 4.102

4.  Structure-function analysis of squirrel monkey FK506-binding protein 51, a potent inhibitor of glucocorticoid receptor activity.

Authors:  Wesley B Denny; Viravan Prapapanich; David F Smith; Jonathan G Scammell
Journal:  Endocrinology       Date:  2005-03-31       Impact factor: 4.736

Review 5.  Novel methods for detecting epistasis in pharmacogenomics studies.

Authors:  Alison A Motsinger; Marylyn D Ritchie; David M Reif
Journal:  Pharmacogenomics       Date:  2007-09       Impact factor: 2.533

6.  FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells.

Authors:  Gabriela M Wochnik; Joëlle Rüegg; G Alexander Abel; Ulrike Schmidt; Florian Holsboer; Theo Rein
Journal:  J Biol Chem       Date:  2004-12-09       Impact factor: 5.157

7.  Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding.

Authors:  W B Denny; D L Valentine; P D Reynolds; D F Smith; J G Scammell
Journal:  Endocrinology       Date:  2000-11       Impact factor: 4.736

8.  A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling.

Authors:  Hayley D McKeen; Kerry McAlpine; Andrea Valentine; Derek J Quinn; Keeva McClelland; Christopher Byrne; Martin O'Rourke; Sheila Young; Christopher J Scott; Helen O McCarthy; David G Hirst; Tracy Robson
Journal:  Endocrinology       Date:  2008-07-31       Impact factor: 4.736

9.  Global strategy for asthma management and prevention: GINA executive summary.

Authors:  E D Bateman; S S Hurd; P J Barnes; J Bousquet; J M Drazen; J M FitzGerald; P Gibson; K Ohta; P O'Byrne; S E Pedersen; E Pizzichini; S D Sullivan; S E Wenzel; H J Zar
Journal:  Eur Respir J       Date:  2008-01       Impact factor: 16.671

10.  Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability.

Authors:  Harry Vermeer; Brenda I Hendriks-Stegeman; Bart van der Burg; Sylvia C van Buul-Offers; Maarten Jansen
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

View more
  13 in total

Review 1.  Glucocorticoid sensitivity in health and disease.

Authors:  Rogier A Quax; Laura Manenschijn; Jan W Koper; Johanna M Hazes; Steven W J Lamberts; Elisabeth F C van Rossum; Richard A Feelders
Journal:  Nat Rev Endocrinol       Date:  2013-10-01       Impact factor: 43.330

2.  Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial.

Authors:  Suzanne Schuh; Judy Sweeney; Maggie Rumantir; Allan L Coates; Andrew R Willan; Derek Stephens; Eshetu G Atenafu; Yaron Finkelstein; Graham Thompson; Roger Zemek; Amy C Plint; Jocelyn Gravel; Francine M Ducharme; David W Johnson; Karen Black; Sarah Curtis; Darcy Beer; Terry P Klassen; Darcy Nicksy; Stephen B Freedman
Journal:  JAMA       Date:  2020-11-24       Impact factor: 56.272

3.  Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.

Authors:  Ekaterina Lesovaya; Alexander Yemelyanov; Kirill Kirsanov; Alexander Popa; Gennady Belitsky; Marianna Yakubovskaya; Leo I Gordon; Steven T Rosen; Irina Budunova
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 4.  Stratified approaches to the treatment of asthma.

Authors:  Stephen T Holgate
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

5.  Impaired nuclear translocation of the glucocorticoid receptor in corticosteroid-insensitive airway smooth muscle in severe asthma.

Authors:  Po-Jui Chang; Charalambos Michaeloudes; Jie Zhu; Nooreen Shaikh; Josephine Baker; Kian Fan Chung; Pankaj K Bhavsar
Journal:  Am J Respir Crit Care Med       Date:  2015-01-01       Impact factor: 30.528

6.  Hypothalamic-pituitary-adrenal axis dysfunction and illness progression in bipolar disorder.

Authors:  Gabriel Rodrigo Fries; Mirela Paiva Vasconcelos-Moreno; Carolina Gubert; Bárbara Tietböhl Martins Quadros dos Santos; Juliana Sartori; Bárbara Eisele; Pamela Ferrari; Adam Fijtman; Joëlle Rüegg; Nils Christian Gassen; Flávio Kapczinski; Theo Rein; Márcia Kauer-Sant'Anna
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

Review 7.  Discovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity.

Authors:  Ekaterina Lesovaya; Alexander Yemelyanov; Amanda C Swart; Pieter Swart; Guy Haegeman; Irina Budunova
Journal:  Oncotarget       Date:  2015-10-13

8.  Glucocorticoid receptor mutations and clinical sensitivity to glucocorticoid in Chinese multiple sclerosis patients.

Authors:  Tian Song; Haoxiao Chang; Li Du; Linlin Yin; Fudong Shi; Xinghu Zhang
Journal:  Neurol Sci       Date:  2020-04-10       Impact factor: 3.307

9.  Association of eosinophilic inflammation with FKBP51 expression in sputum cells in asthma.

Authors:  Tomoko Tajiri; Hisako Matsumoto; Akio Niimi; Isao Ito; Tsuyoshi Oguma; Hitoshi Nakaji; Hideki Inoue; Toshiyuki Iwata; Tadao Nagasaki; Yoshihiro Kanemitsu; Guergana Petrova; Michiaki Mishima
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

10.  FKBP51 modulates steroid sensitivity and NFκB signalling: A novel anti-inflammatory drug target.

Authors:  Marc Kästle; Barbara Kistler; Thorsten Lamla; Tom Bretschneider; David Lamb; Paul Nicklin; David Wyatt
Journal:  Eur J Immunol       Date:  2018-09-14       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.